his.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
In vitro study of the antiproliferative properties of Digitoxin glycosides and Keytruda on BxPC-3 pancreatic cancer
Högskolan i Skövde, Forskningsspecialiseringen Hälsa och Lärande.
2019 (Engelska)Självständigt arbete på grundnivå (kandidatexamen), 20 poäng / 30 hpStudentuppsats (Examensarbete)
Abstract [en]

In the early 1900s, cancer patients were often treated by inducing a bacterial infection that stimulated an immune response which lead to a spontaneous passive cancer regression. This discovery lead to today’s modern cancer immunotherapy – an approach in which medical interventions stimulate the body’s own immune system to fight cancer cells. Digitoxin glycosides, a sodium pump inhibitor used mainly to treat heart-related diseases has been reviewed in clinical trials for its anti-tumor like properties. Moreover, A new drug to aid in the war against progressive inoperable metastatic cancers was approved 2014 by FDA. Keytruda was the first monoclonal non-chimeric human IgG4 antibody drug to restore the immune response to activated T-cells by interfering with the tumours’ programmed death ligands (PD-L1) and (PD-L2). Cancer cells express an increased level of reactive oxygen species (ROS) that promote cancer cell proliferation and development. However, in too low or high levels, ROS promote oxidative damage in favour of anti-tumor properties. This study evaluated Digitoxin glycosides and Keytruda as potential anti-tumor therapies and any eventual synergic effects. Digitoxin, as mono-therapy, promoted apoptotic behaviour in pancreatic cancer cells when administrated in the mid- to high-end dosage range. Respectively, this study suggests a combination-therapy using a sub-physiological Keytruda-concentration together with a relatively high Digitoxin concentration produce a significant antiproliferative effect.

Ort, förlag, år, upplaga, sidor
2019. , s. 30
Nyckelord [en]
cytotoxic t lymphocytes, epidermal growth factor, fetal bovine serum, interferon gamma, immunoglobulin g, interleukin-1, monoclonal antibodies, natural killer cells, programmed death ligands, programmed death receptor, polymerase chain reaction, reactive oxygen species, tumor necrosis factor alpha, transforming growth factor β
Nationell ämneskategori
Annan biologi Biomedicinsk laboratorievetenskap/teknologi
Identifikatorer
URN: urn:nbn:se:his:diva-17591OAI: oai:DiVA.org:his-17591DiVA, id: diva2:1346034
Externt samarbete
Johan Haux, medical consultant & cancer researcher
Ämne / kurs
Biomedicin/medicinsk vetenskap
Utbildningsprogram
Biomedicinprogrammet
Handledare
Examinatorer
Tillgänglig från: 2019-08-28 Skapad: 2019-08-27 Senast uppdaterad: 2019-08-28Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Sök vidare i DiVA

Av författaren/redaktören
Svensson, Andreas
Av organisationen
Forskningsspecialiseringen Hälsa och Lärande
Annan biologiBiomedicinsk laboratorievetenskap/teknologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 62 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf